Wire · opportunities
Dyne Therapeutics' z-rostudirsen Wins Priority Review for Duchenne Muscular Dystrophy
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 July 2026 · Fusion42 review
Dyne Therapeutics' z-rostudirsen has received FDA Priority Review designation for Duchenne muscular dystrophy patients amenable to exon 51 skipping, compressing the standard 10-month review to six months. The approval decision could arrive before the Phase 3 FORZETTO confirmatory trial completes, placing full regulatory weight on the dystrophin biomarker data already submitted in the BLA.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building muscle dystrophin biomarkers or patient stratification tools for exon-skipping programmes, the approval bar just shifted: regulatory decisions are now happening on day-one data, not trial data that lands later. That means your assay needs clinical-grade precision from month one, and you have six months to prove it works.
◆ Coverage
1 source · 21 Jul 2026
◆ Related on Wire
◆ Topics